By the end of 2017, CTS has secured three source plasma partners and continues to seek additional partners in the plasma industry in order to continue to diversify CTS’s revenue stream.
In July, the six viral marker assay conversion at CTS Dallas, Phoenix and Tampa laboratories was ach...
As a component of the CTS Business Continuity Plan, today all 6 labs began using the same laboratory...
CTS Tampa lab implemented the Ortho Clinical Diagnostics VITROS® testing platform to perform COVID-1...
CTS Research Consortium was established to further CTS’s leadership in infectious disease research....
In August CTS begins source plasma testing as a new line of business to one of the largest plasma fr...
In January, CTS is incorporated as a non-profit organization owned by Vitalant and OneBlood (formerl...